Market Intelligence, Clinical Progress, and High-Purity Reagents for Eosinophilic Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Galectin 10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Galectin 10 (CLC) Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View Galectin 10 Products |
| Gene Delivery | Galectin 10 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View Galectin 10 Products |
| Benchmark Ab | Anti-Galectin 10 Recombinant Antibody Recombinant positive control biosimilar. |
View Galectin 10 Products |
| Validator | Galectin 10 siRNA Set For knockdown verification. |
View Galectin 10 Products |
| Related Target A | IL-5 Key cytokine driving eosinophil differentiation and survival, acting upstream of CLC release. |
View IL-5 Products |
| Related Target B | IL-5RA Target for eosinophil depletion, highly synergistic with crystal-dissolving therapies. |
View IL-5RA Products |
| Related Target C | Siglec-8 Synergistic pathway for eosinophil depletion. |
View Siglec-8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| In vitro crystal formation for dissolution assays | High-purity recombinant Galectin 10 with verified sequence and theoretical MW, ensuring reproducible crystallization. |
| Subfamily counter-screening (selectivity vs. other Galectins) | Comprehensive Galectin homolog panel (Galectin-1, 3, 8, 9) strictly verified by mass spectrometry. |
| Cross-species Evaluation | Human and Cyno ortholog proteins available, strictly verified by mass spec. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live Galectin 10/CLC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Galectin 10/CLC therapeutics is intensifying, with major players shifting focus from broad immunosuppressants to targeted crystal-dissolving monoclonal antibodies. As first-generation therapies such as crystal-dissolving antibodies reach clinical evaluation, the next wave of R&D is targeting the direct neutralization of Charcot-Leyden Crystals (CLCs) to resolve severe airway inflammation and tissue damage. Key indications include severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), and allergic rhinitis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Crystal-Dissolving) | argenx (ARGX-118), Sanofi, VIB | Severe Asthma, CRSwNP | Crystal Dissolution Assay (Need high-purity, crystallization-competent protein) |
| Bispecific Antibody | Emerging Biotechs | Eosinophilic Esophagitis | Heterodimer Validation (Need Cross-reactive Abs) |
| Small Molecule (Crystal Formation Inhibition) | Academic Institutions, Spin-offs | Eosinophilic Esophagitis, Allergic Rhinitis | Selectivity & Binding Affinity Assays (Need high-purity protein and homolog panel) |